GenoMed Research Takes Off
CONTACT: GenoMed Inc.
David W. Moskowitz, MD, MA, FACP
(314) 652-0500
dwmoskowitz@genomedics.com
For Immediate Release - ST. LOUIS, MO. – June 8, 2004 – GenoMed, Inc. (Pink Sheets: GMED), a Next Generation DM™ (Disease Management) company that uses its expertise in medical genomics to improve clinical outcomes, announced today that it has hired a Chief Scientific Officer and launched its large-scale genotyping project with Genome Quebec.
Dr. Paula M. Hempen was hired as Chief Scientific Officer. She earned her PhD in the Department of Microbiology and Immunology at the University of Kentucky, where she co-authored four papers on the regulation of the immunoglobulin receptor gene. She next completed a three-year post-doc on the genetics of pancreatic cancer at Johns Hopkins University School of Medicine, where she co-authored another five papers. She has extensive teaching experience at the high school, undergraduate, and graduate school levels.
Said Dr. David Moskowitz, GenoMed's CEO and Chairman, "I'm delighted to have Dr. Hempen join us full-time, now that we are financially healthy enough to make use of her many talents. She first expressed her interest in GenoMed nearly two years ago. Her experience in cancer genetics, her down-to-earth manner, her perseverance, and her skill at explaining complex subjects will be extremely helpful. She and our Chief Technical Officer Andy O'Guin are already constructing a larger Disease GeneNet for us to use to capture cancer-causing genes."
GenoMed also recently sent 22,000 SNPs to Genome Quebec to begin its large-scale genotyping project to find genes which cause common cancers. Any genes which GenoMed finds will be patented and used as an early warning system to enable early, cost-effective screening of patients at high risk of cancer. These cancer genes will thus have diagnostic value almost immediately. But as drug targets, cancer genes may prove difficult. For example, no drugs have yet been designed against BRCA 1 or 2, the breast cancer genes discovered a decade ago.
About GenoMed
GenoMed is leading the worldwide medical revolution which medical genomics has already made possible. In addition to looking for new disease-predisposition genes, the Company is currently marketing its treatment to prevent kidney failure due to diabetes and high blood pressure, and to delay emphysema. GenoMed is currently conducting a global trial against West Nile virus encephalitis and other lethal viruses.
. |
